Cassava Sciences CEO Remi Barbier Maintains Significant SAVA Stake

TL;DR

**Cassava Sciences CEO Remi Barbier still owns over 2.4M shares, signaling strong insider confidence.**

AI Summary

Remi Barbier, CEO of Cassava Sciences Inc. (SAVA), filed an amended SC 13G/A on February 1, 2024, disclosing his beneficial ownership of 2,488,531 shares of common stock as of December 31, 2023. This represents a significant stake, with Barbier holding sole voting and dispositive power over 1,778,465 shares and shared voting and dispositive power over 710,066 shares. This matters to investors because it shows the CEO's continued substantial personal investment in the company, potentially signaling confidence in its future, especially given the ongoing clinical trials for its Alzheimer's drug, simufilam.

Why It Matters

This filing indicates that Cassava Sciences' CEO, Remi Barbier, continues to hold a substantial personal investment in the company, which can be interpreted as a vote of confidence in its prospects and ongoing drug development.

Risk Assessment

Risk Level: low — This filing is an amendment to a previous disclosure and shows a stable, significant insider holding, which generally reduces perceived risk.

Analyst Insight

A smart investor would note the CEO's continued substantial personal investment as a positive signal, suggesting strong insider confidence in Cassava Sciences' future, and consider it when evaluating the stock, especially in light of ongoing clinical trials.

Key Numbers

• 2,488,531 — Total Shares Beneficially Owned (Remi Barbier's total beneficial ownership in Cassava Sciences Inc. as of December 31, 2023.)
• 1,778,465 — Shares with Sole Voting Power (Shares over which Remi Barbier has sole voting and dispositive control.)
• 710,066 — Shares with Shared Voting Power (Shares over which Remi Barbier has shared voting and dispositive control.)
• December 31, 2023 — Date of Event (The date as of which the beneficial ownership information was reported.)

Key Players & Entities

• Remi Barbier (person) — CEO and Reporting Person for Cassava Sciences Inc.
• Cassava Sciences Inc. (company) — Subject Company, a pharmaceutical preparations firm
• Eric Schoen (person) — Chief Financial Officer of Cassava Sciences Inc.
• 03 Life Sciences (company) — Organization Name associated with the subject company

Forward-Looking Statements

• Remi Barbier will maintain a significant ownership stake in Cassava Sciences Inc. (Remi Barbier) — high confidence, target: December 31, 2024
• Cassava Sciences Inc. will continue its focus on pharmaceutical preparations, specifically its Alzheimer's drug candidate. (Cassava Sciences Inc.) — high confidence, target: December 31, 2024

FAQ

Filing Documents

• rbar20240130_sc13ga.htm (SC 13G/A) — 49KB
• 0001437749-24-002819.txt ( ) — 50KB

(a) Name of Issuer

Item 1. (a) Name of Issuer Cassava Sciences, Inc.

(b) Address of Issuer ' s Principal Executive Offices

Item 1. (b) Address of Issuer ' s Principal Executive Offices 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, TX 78731

(a) Name of Person Filing

Item 2. (a) Name of Person Filing Remi Barbier

(b) Address of the Principal Office or, if none, residence

Item 2. (b) Address of the Principal Office or, if none, residence 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, TX 78731

(c) Citizenship

Item 2. (c) Citizenship USA

(d) Title of Class of Securities

Item 2. (d) Title of Class of Securities Common Stock

(e) CUSIP Number

Item 2. (e) CUSIP Number 14817C 107 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240,13d-1(b)(1)(ii)(J); (k) Group, in accordance with 240.13d-1(b)(1)(ii)(J). CUSIP No. 14817C 107 13G Page 4 of 5 Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 2,488,531 (b) Percent of class: 5.7% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 1,778,465 (ii) Shared power to vote or to direct the vote 710,066 (iii) Sole power to dispose or to direct the disposition of 1,778,465 (iv) Shared power to dispose or to direct the disposition of 710,066 Instruction . For computations regarding securities which represent a right to acquire an underlying security see 240.13d-3(d)(1). Item 5. If this statement is being filed to report the fact that as of the

View Full Filing

View this SC 13G/A filing on SEC EDGAR